Korean Drug Co. Ltd (014570) — Cash Flow Quality Index

Latest as of March 2026: 5.49x

Korean Drug Co. Ltd (014570) has a Cash Flow Quality Index of 5.49x as of March 2026. Operating cash flow of ₩6.60 Billion exceeds net income of ₩1.20 Billion, indicating high earnings quality where cash backs reported profits. Explore 014570 cash flow metrics to assess how effectively this company generates cash.

Cash Flow Quality Index

5.49x
Operating CF / Net Income

Operating Cash Flow

₩6.60 Billion
KRW

Net Income

₩1.20 Billion
KRW

Data as of

Mar 2026
Most recent filing

Korean Drug Co. Ltd Cash Flow Quality Index (2014–2025)

Historical Cash Flow Quality Index for Korean Drug Co. Ltd across 11 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Korean Drug Co. Ltd (014570) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Cash Flow Quality Index for Korean Drug Co. Ltd (2014–2025)

Year-by-year earnings quality comparison for Korean Drug Co. Ltd. For live market cap and the full company financial profile, see Korean Drug Co. Ltd market capitalisation.

Year Quality Index Operating CF (KRW) Net Income YoY Change
2025 2.01x ₩13.11 Billion ₩6.51 Billion ▲ +23.8%
2024 1.63x ₩4.87 Billion ₩3.00 Billion ▲ +224.7%
2022 0.50x ₩5.91 Billion ₩11.81 Billion ▼ -48.6%
2021 0.97x ₩8.81 Billion ₩9.04 Billion ▼ -41.9%
2020 1.68x ₩12.33 Billion ₩7.36 Billion ▲ +5.1%
2019 1.59x ₩6.21 Billion ₩3.90 Billion ▲ +80.7%
2018 0.88x ₩5.79 Billion ₩6.56 Billion ▲ +823.6%
2017 0.10x ₩447.20 Million ₩4.68 Billion ▼ -87.8%
2016 0.78x ₩3.96 Billion ₩5.05 Billion ▼ -77.3%
2015 3.46x ₩6.13 Billion ₩1.77 Billion ▲ +66.7%
2014 2.07x ₩4.46 Billion ₩2.15 Billion
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.